Oxford, UK — Manchester-based biotech firm Gentronix today announced the company's first contracted screening project in Japan, with major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline.
On the back of growing sales in America and Europe, Gentronix identified Japan as a key market and turned to Intralink’s Surrogate Sales Program™, to provide a physical presence on the ground, drive sales and support local customers.
The programme enabled Gentronix to establish a local representative office and, via Intralink’s bilingual staff based in Tokyo, a local sales team – without the costs or risks associated with setting up and operating in a new market.
Gentronix Chairman and CEO, John Nicholson commented “Gentronix is delighted to have closed its first deal in Japan, and we have been really impressed with the thoroughness and professionalism of the Intralink team. They quickly grasped the essence of what is a fairly complex technology and their understanding of the language, culture and business practices of both buyer and seller makes them an ideal partner in this market."
About Intralink Intralink develops and implements market access and business development strategies for technology and industrial companies targeting the key Asian markets of China, Japan, Korea and Taiwan. Through its signature Surrogate Sales Program™, Intralink provides its clients with a low-risk, cost-effective and practical means to generate new and incremental revenues in these markets as an underpin towards establishing a permanent presence. Founded in 1990, Intralink is headquartered in the UK and has offices in Silicon Valley, Tokyo, Shanghai, Taipei and Seoul.
About Gentronix Gentronix is a Manchester University spin-out company that provides services and solutions that help companies optimize the development of drugs and other chemicals, by reducing rates of attrition due to toxicity and ensuring safer products across a wide range of chemistry driven industries.
Intralink Contact Alex Gover alex.gover@intralink-uk.com +44 20 8960 3817